Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

BlossomHill Therapeutics, Inc.

NASDAQ: BLSM · Life Sciences · 4 alerts · CIK 1839970

Share price
$13.65Close, Nov 16
Market cap
$434M
Shares outstanding
31.78MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BlossomHill Therapeutics, Inc. filings on SEC EDGAR ↗

7:30 AM ET 8-K
Clinical Trial Data

BlossomHill Therapeutics Clinical Trial Data

BlossomHill Therapeutics announced updated Phase 1/2 SOLARA trial data for BH-30643 in patients with EGFR C797S-positive NSCLC, showing a 45% objective response rate and 88% disease control rate. The results, presented at the 2026 World Conference on Lung Cancer, demonstrate the drug's potential to overcome resistance to existing EGFR inhibitors in a population with no approved targeted therapies. The company plans to advance the candidate into a Phase 2 trial in 2027 following its recent FDA Fast Track designation.

Counterparty
International Association for the Study of Lung Cancer (IASLC)

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.